A major cancer drugmaker may need to buy its way out of a looming disaster By: CNBC.com News January 18, 2018 at 13:24 PM EST Buying Juno could help Celgene diversify its portfolio as its top-selling drug approaches patent expiration. Read More >> Related Stocks: Bluebird Bio Celgene Corp Gilead Sciences Novan Inc